Рубрика
Blog
-
2023
-
GSK’s Jemperli Gets Regular Approval for Endometrial Cancer
-
FDA Accepts Biologics License Application for Proposed Biosimilar Denosumab
-
FDA Extends Ibuprofen Suspension Guidance
-
FDA Approves Regeneron’s Eylea for Infants With ROP
-
FDA Expands Approval for Takeda’s Takhzyro
-
Mesoblast Cell Therapy Gets RMAT Designation for Chronic Low Back Pain
-
EMA Clarifies Its Policy on Biosimilar Interchangeability
-
Janssen’s Nipocalimab Shines in HDFN Trial
-
Rocket Pharmaceuticals Gets RMAT Designation for Danon Disease Gene Therapy
-
Sage and Biogen’s Depression Drug Candidate Gets Priority Review